Suchergebnisse - "Ruan, Gordon J"

PubPharm (31)

1

Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis

enthalten in: American journal of hematology | 2024

von Ruan, G. | Zanwar, S. | Ravindran, A. | +12

2

Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis

enthalten in: American Journal of Hematology | 2024

von Ruan, G. | Zanwar, S. | Ravindran, A. | +11

3

Long-term outcomes among adults with Langerhans cell histiocytosis

enthalten in: Blood advances | 2023

von Goyal, G. | Acosta-Medina, A. | Abeykoon, J. | +17

4

Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells

enthalten in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2023

von Ravindran, A. | Dasari, S. | Ruan, G. | +10

5

Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19

enthalten in: iScience | 2023

von Wu, X. | Manske, M. | Ruan, G. | +16

6

Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status

enthalten in: JAMA oncology | 2022

von Abeykoon, J. | Rech, K. | Young, J. | +19

7

Classical and non-classical phenotypes of Erdheim-Chester disease : Correlating clinical, radiographic and genotypic findings

enthalten in: British journal of haematology | 2022

von Hazim, A. | Acosta-Medina, A. | Young, J. | +14

8

Secreted ORF8 is a pathogenic cause of severe COVID-19 and is potentially targetable with select NLRP3 inhibitors

enthalten in: bioRxiv.org | 2022

von Wu, X. | Manske, M. | Ruan, G. | +16

9

Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease

enthalten in: American journal of hematology | 2022

von Abeykoon, J. | Lasho, T. | Dasari, S. | +22

10

A single-institution retrospective study of causes of prolonged prothrombin time and activated partial thromboplastin time in the outpatient setting

enthalten in: International journal of laboratory hematology | 2022

von Hazim, A. | Ruan, G. | Khodadadi, R. | +3